Privia Health Group’s (PRVA) “Overweight” Rating Reaffirmed at Stephens

Stephens reissued their overweight rating on shares of Privia Health Group (NASDAQ:PRVA) in a research note issued to investors on Thursday,Benzinga reports. Stephens currently has a $32.00 price objective on the stock.

Several other research firms have also recently weighed in on PRVA. Canaccord Genuity Group increased their price objective on Privia Health Group from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Truist Financial reissued a “buy” rating and issued a $31.00 price target (up from $30.00) on shares of Privia Health Group in a report on Monday, November 10th. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research report on Monday. Barclays upped their price objective on shares of Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Finally, JMP Securities lifted their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a “market outperform” rating in a research report on Friday, August 29th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Privia Health Group Price Performance

PRVA stock opened at $24.00 on Thursday. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 184.63, a price-to-earnings-growth ratio of 4.05 and a beta of 0.83. The company has a 50-day moving average of $24.48 and a two-hundred day moving average of $22.77. Privia Health Group has a 52-week low of $18.77 and a 52-week high of $26.51.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Tuesday, June 7th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $213.61 million during the quarter. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%. Equities analysts expect that Privia Health Group will post 0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock valued at $301,263,000 after purchasing an additional 607,447 shares during the period. Durable Capital Partners LP boosted its stake in Privia Health Group by 1.8% in the 3rd quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after buying an additional 203,842 shares in the last quarter. State Street Corp grew its position in Privia Health Group by 1.5% in the second quarter. State Street Corp now owns 4,171,069 shares of the company’s stock valued at $95,935,000 after acquiring an additional 61,853 shares during the period. Van Berkom & Associates Inc. grew its position in Privia Health Group by 30.1% in the third quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock valued at $93,987,000 after acquiring an additional 873,344 shares during the period. Finally, Geode Capital Management LLC raised its stake in Privia Health Group by 6.3% during the second quarter. Geode Capital Management LLC now owns 2,655,569 shares of the company’s stock worth $61,086,000 after acquiring an additional 158,521 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.